Locoregional Recurrence Risk in Breast Cancer Patients with Estrogen Receptor Positive Tumors and Residual Nodal Disease following Neoadjuvant Chemotherapy and Mastectomy without Radiation Therapy

Table 4

ypN/receptor groups associated with a ≤10% five-year LRR risk.

	5-year risk of LRR
ypN+
ER+	5%
ypN0
ER+	7%
Triple negative	6%

LRR, locoregional recurrence.
denotes LRR risk without specification of other adverse pathological features.